The NHS will expand the use of the respiratory syncytial virus vaccine in England to cover millions more older people as health authorities aim to ease the seasonal burden on hospitals from respiratory infections.
From April 2026, all adults aged 80 and over and residents of aged care homes will be able to receive the respiratory syncytial virus vaccine.
The policy shift will significantly expand the program, which previously targeted people aged 75 to 79 and those turning 75, starting in 2024.
Michelle Kane, NHS Director of Vaccination and Screening Delivery, urged people to get vaccinated as soon as possible, saying: “Responsive virus virus (RSV) is not just a winter disease, it can occur all year round and can cause serious illness in older people, so it’s vital everyone gets vaccinated.”
“Vaccines have been shown to significantly reduce the likelihood of hospitalization for RSV infection in people over 75, so if you are meeting a loved one or family member who is eligible for vaccination over the Easter holidays, please ask them to come forward when invited.
“If you’re newly eligible or haven’t come forward yet, don’t put it off and book your free NHS vaccination with your GP or speak to staff at your care home. This could help prevent you from developing serious illnesses such as pneumonia and may even save your life.”
Growing concern about RSV in an aging society
RSV is a widespread respiratory pathogen that usually causes mild cold-like symptoms.
However, in older people, especially those with underlying health conditions, it can cause serious complications such as pneumonia, bronchitis, and exacerbation of chronic lung disease.
These complications often require hospital treatment. Health data shows that around 9,000 people over 75 are admitted to hospital each year in the UK with RSV.
Clinicians note that the virus severely impairs the breathing of vulnerable patients and could increase both morbidity and medical demand during peak seasons.
Vaccination strategy and expected impact
Health officials hope the expansion of the RSV vaccine program will help reduce these hospitalizations because a single dose provides long-term protection, which evidence shows lasts for several years.
The decision to expand eligibility reflects both demographic trends and health system pressures, particularly during the winter months when respiratory illnesses spike. By targeting those most at risk, policymakers aim to reduce avoidable hospitalizations and improve outcomes for older adults.
How to get RSV vaccine
Eligible individuals can arrange vaccination through their GP. In addition, care home staff are facilitating access for residents and selected community pharmacies in parts of England are participating in the rollout.
The NHS also maintains eligibility for previous priority groups. Adults ages 75 to 79 who have not yet been vaccinated will continue to be eligible, as will individuals turning 75.
Pregnant women can continue to receive the RSV vaccine starting at 28 weeks of pregnancy to protect newborns from serious respiratory infections early on.
Widespread impact on public health
The expansion of respiratory syncytial virus vaccine programs highlights the increased focus on prevention strategies in an aging population.
With respiratory syncytial virus contributing significantly to the winter health strain, increasing vaccine uptake among high-risk groups could play a measurable role in reducing system strain while improving patient outcomes.
Source link
